Gene Editing Firm Editas Medicine Raises $43M in Series A Round | GenomeWeb

NEW YORK (GenomeWeb News) – Gene editing firm Editas Medicine today announced it has secured $43 million in Series A financing.

The financing was led by Flagship Ventures, Polaris Partners, and Third Rock Ventures. Partners Innovation Fund also participated.

Editas plans to use its genome editing technology to develop new therapeutics “that enable precise and corrective molecular modification to treat the underlying cause of a broad range of diseases at the genetic level.”

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Nature this week: genetic link between birth weight and adult-onset diseases, and more.

Even with all the current enthusiasm for gene therapies, Tech Review cautions that they are mostly in the early stages of development.

DNA phenotyping puts a potential face to a suspect in a nearly 25-year-old murder, the AP reports.

Researchers discuss the need for antibody standards at a meeting, NPR reports.